All figures are in US$ million unless stated otherwise	2017-18  Constant Currency(1)	2017-18  Reported(2)	2016-17  Reported	2015-16 Reported	2014-15  Reported	2013-14 Reported
Total Operating Revenue	7,717	7,915	6,947	6,115	5,612	5,504
Sales Revenue	7,394	7,588	6,616	5,909	5,459	5,335
R&D Investment	685	702	667	614	463	466
Profit before Income Tax Expense	2,260	2,281	1,690	1,556	1,714	1,604
Net profit after tax	1,713	1,729	1,337	1,242	1,379	1,307
Net cash inflow from Operating Activities		1,902	1,247	1,179	1,364	1,361
Capital investment		992	861	566	414	402
Return on Invested Capital (%)		25.9	24.5	26.8%(3)	31.70%	31.80%
Basic earnings per share ($)		3.822	2.937	2.689	2.923	2.701
Dividend per share ($)		1.720	1.360	1.26	1.24	1.13

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial
Statements for the Full Year ended 2018 (Directors’ Report).
(2) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1 million.